Inovio

$11.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.38 (+3.42%) As of 3:34 PM UTC today

Why Robinhood?

You can buy or sell Inovio and other stocks, options, and ETFs commission-free!

About INO

Inovio Pharmaceuticals, Inc. Common Stock, also called Inovio, is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA. The listed name for INO is Inovio Pharmaceuticals, Inc. Common Stock.

CEO
J. Joseph Kim
Employees
194
Headquarters
Plymouth Meeting, Pennsylvania
Founded
1983
Market Cap
2.39B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
17.44M
High Today
$11.57
Low Today
$11.24
Open Price
$11.44
Volume
2.71M
52 Week High
$33.79
52 Week Low
$3.83

INO News

MarketWatchFeb 26

Inovio Pharmaceuticals Inc. stock falls Friday, underperforms market

Shares of Inovio Pharmaceuticals Inc. INO, -3.39% shed 3.39% to $11.10 Friday, on what proved to be an all-around mixed trading session for the stock market, wi

INO Earnings

-$0.38
-$0.25
-$0.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.22 per share
Actual
Available Today, After Hours
Preview Earnings Call

You May Also Like

LSXMA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure